Transcriptomic Profiling of Obesity-Related Nonalcoholic Steatohepatitis Reveals a Core Set of Fibrosis-Specific Genes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Nonalcoholic steatohepatitis (NASH) is strongly associated with obesity and type 2 diabetes. The molecular factors underlying the development of inflammation and severe fibrosis in NASH remain largely unknown. The purpose of this study was to identify gene expression patterns related to obesity-related NASH inflammation and fibrosis. We performed sequencing-based mRNA profiling analysis of liver samples from individuals with normal histology (n = 24), lobular inflammation (n = 53), or bridging fibrosis, incomplete cirrhosis, or cirrhosis (n = 65). Hepatic expression of a subset of mRNAs was validated using an orthogonal method, analyzed in a hepatic stellate cell line, and used to identify transcriptional patterns shared by other forms of cirrhosis. We observed evidence for differential levels of 3820 and 2980 transcripts in lobular inflammation and advanced fibrosis, respectively, compared with normal histology (false discovery rate ≤0.05), including 176 genes specific to fibrosis. Functional enrichment analysis of these genes revealed participation in pathways involving cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, focal adhesion, and extracellular matrix-receptor interaction. We identified 34 differentially expressed transcripts in comparisons of lobular inflammation and fibrosis, a proportion of which were also upregulated during activation of hepatic stellate cells. A set of 16 genes from a previous independent study of NASH bridging fibrosis/cirrhosis were replicated, several of which have also been associated with advanced fibrosis/cirrhosis due to hepatitis viruses or alcohol in human patients. Dysregulated mRNA expression is associated with inflammation and fibrosis in NASH. Advanced NASH fibrosis is characterized by distinct set of molecular changes that are shared with other causes of cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Clinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411 · cited 1×
“NASH fibrosis is considered to be a dynamic process resulting from both qualitatively and quantitatively abnormal ECM deposition [63].”
BackgroundDiabetes and cause-specific mortality in a prospective cohort of one million U.S. Adults
Campbell, P. T., Newton, C. C., Patel, A. V., Jacobs, E. J., & Gapstur, S. M. (2012) · Diabetes Care · doi:10.2337/dc12-0002 · Cited by 339 · cited 4×
“Lipotoxicity, oxidative stress, cytokines, and other inflammatory molecules have been implicated in the molecular mechanisms leading to the progression of inflammation to fibrosis in NAFLD/NASH in the setting of risk factors such as obesity [8] and T2D [9, 10].”
BackgroundInfluentialNKT-Associated Hedgehog and Osteopontin Drive Fibrogenesis in Non-Alcoholic Fatty Liver Disease
Syn, W.-K., Agboola, K. M., Swiderska, M., Michelotti, G. A., Liaskou, E., Pang, H., Xie, G., Philips, G., Chan, I. S., Karaca, G. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301857 · Cited by 266
Teufel, A., Itzel, T., Erhart, W., Brosch, M., Wang, X. Y., Kim, Y. O., von Schönfels, W., Herrmann, A., Brückner, S., Stickel, F., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.05.051 · Cited by 229 · cited 1×
“However, a recent study comparing hepatic gene expression in nine NAFLD mouse models with transcriptional changes in human liver biopsies found little evidence of overlap between species [70].”
BackgroundBauer, Y., White, E. S., de Bernard, S., Cornelisse, P., Leconte, I., Morganti, A., Roux, S., & Nayler, O. (2017) · ERJ Open Research · doi:10.1183/23120541.00074-2016 · Cited by 139
Lefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117 · cited 1×
“Nevertheless, a paired biopsy approach has been reported [72], although only one patient with cirrhosis was analyzed.”
Background
Cited by
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
Polyzos, S. A., Kountouras, J., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.014 · Cited by 1,211
Govaere, O., Cockell, S., Tiniakos, D., Queen, R., Younes, R., Vacca, M., Alexander, L., Ravaioli, F., Palmer, J., Petta, S., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aba4448 · Cited by 479
Suppli, M. P., Rigbolt, K. T. G., Veidal, S. S., Heebøll, S., Eriksen, P. L., Demant, M., Bagger, J. I., Nielsen, J. C., Oró, D., Thrane, S. W., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00358.2018 · Cited by 282
Clonal haematopoiesis and risk of chronic liver disease
Wong, W. J., Emdin, C., Bick, A. G., Zekavat, S. M., Niroula, A., Pirruccello, J. P., Dichtel, L., Griffin, G., Uddin, M. M., Gibson, C. J., et al. (2023) · Nature · doi:10.1038/s41586-023-05857-4 · Cited by 220
Zimmermann, T., Thomas, L., Baader-Pagler, T., Haebel, P., Simon, E., Reindl, W., Bajrami, B., Rist, W., Uphues, I., Drucker, D. J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101633 · Cited by 149
“Furthermore, the transcriptional changes in genes such as IHH [87], DDAH [88], Nox4 [89], and COX6B2 [90] suggest potential hepatoprotective pathways that comprise anti-fibrotic, anti-inflammatory, and anti-oxidative effects.”
BackgroundSingle-cell and bulk transcriptomics of the liver reveals potential targets of NASH with fibrosis
Wang, Z.-Y., Keogh, A., Waldt, A., Cuttat, R., Neri, M., Zhu, S., Schuierer, S., Ruchti, A., Crochemore, C., Knehr, J., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-98806-y · Cited by 103
Fred, R. G., Steen Pedersen, J., Thompson, J. J., Lee, J., Timshel, P. N., Stender, S., Opseth Rygg, M., Gluud, L. L., Bjerregaard Kristiansen, V., Bendtsen, F., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16754-7 · Cited by 44
Johnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01129-y · Cited by 43
Self-citationMulticytokine-producing CD4+ T cells characterize the livers of patients with NASH
Woestemeier, A., Scognamiglio, P., Zhao, Y., Wagner, J., Muscate, F., Casar, C., Siracusa, F., Cortesi, F., Agalioti, T., Müller, S., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.153831 · Cited by 28
“To further confirm our findings in a different cohort of patients, we used a publicly available human NASH bulk RNA-seq data set (32), and found a significant correlation between the expression of IL17A and COL1A1 (Supplemental Figure 5E).”
Method
Metadata
- Authors
- Gerhard, G. S., Legendre, C., Still, C. D., Chu, X., Petrick, A., & DiStefano, J. K.
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2018-06-05
- Volume
- 2
- Issue
- 7
- Pages
- 710-726
- ISSN
- 2472-1972 (ISSN-L)
- OpenAlex
- W2807500148
- Cited by
- 70
- References
- 9
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.